231 related articles for article (PubMed ID: 1868486)
21. The incubation of human blood monocytes with tumor necrosis factor-alpha leads to lysis of tumor necrosis factor-sensitive but not resistant tumor cells.
Nii A; Fidler IJ
Lymphokine Res; 1990; 9(2):113-24. PubMed ID: 2338840
[TBL] [Abstract][Full Text] [Related]
22. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
Fidler IJ; Fan D; Ichinose Y
Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047
[TBL] [Abstract][Full Text] [Related]
23. Lipopolysaccharide and liposome-encapsulated MTP-PE-induced cytotoxicity and release of eicosanoids, tumor necrosis factor- alpha and nitric oxide in liver macrophages.
Dieter P; Ambs P; Fitzke E; Schwende H
Adv Exp Med Biol; 1997; 407():485-90. PubMed ID: 9321995
[No Abstract] [Full Text] [Related]
24. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.
Kleinerman ES; Erickson KL; Schroit AJ; Fogler WE; Fidler IJ
Cancer Res; 1983 May; 43(5):2010-4. PubMed ID: 6831430
[TBL] [Abstract][Full Text] [Related]
25. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide.
Goldbach P; Dumont S; Kessler R; Poindron P; Stamm A
Am J Physiol; 1996 Mar; 270(3 Pt 1):L429-34. PubMed ID: 8638735
[TBL] [Abstract][Full Text] [Related]
26. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
[TBL] [Abstract][Full Text] [Related]
27. Liposome encapsulation of muramyl peptides for activation of macrophage cytotoxic properties.
Nayar R; Schroit AJ; Fidler IJ
Methods Enzymol; 1986; 132():594-603. PubMed ID: 3547028
[No Abstract] [Full Text] [Related]
28. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
Phillips NC; Rioux J; Tsao MS
Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
[TBL] [Abstract][Full Text] [Related]
29. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
30. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.
Hisano G; Fidler IJ
Cancer Immunol Immunother; 1982; 14(2):61-6. PubMed ID: 6965228
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs.
Bezault J; Walsh C; Tarcsay L; Frost H; Liebes L; Furmanski P
In Vivo; 1993; 7(6A):487-91. PubMed ID: 8193265
[TBL] [Abstract][Full Text] [Related]
32. Induction of macrophage antitumor activity by acetylated low density lipoprotein containing lipophilic muramyl tripeptide.
Shaw JM; Futch WS; Schook LB
Proc Natl Acad Sci U S A; 1988 Aug; 85(16):6112-6. PubMed ID: 3413079
[TBL] [Abstract][Full Text] [Related]
33. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.
Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ
J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228
[TBL] [Abstract][Full Text] [Related]
34. Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients.
Sone S; Utsugi T; Tandon P; Yanagawa H; Okubo A; Ogura T
Cancer Immunol Immunother; 1990; 30(6):357-62. PubMed ID: 2302725
[TBL] [Abstract][Full Text] [Related]
35. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW
J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598
[TBL] [Abstract][Full Text] [Related]
36. Modulation of pulmonary macrophage superoxide release and tumoricidal activity following activation by biological response modifiers.
Drath DB
Immunopharmacology; 1986 Oct; 12(2):117-26. PubMed ID: 3021650
[TBL] [Abstract][Full Text] [Related]
37. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis.
Killion JJ; Fidler IJ
Immunomethods; 1994 Jun; 4(3):273-9. PubMed ID: 7820457
[TBL] [Abstract][Full Text] [Related]
38. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
39. Intracellular activation of tumoricidal properties in mouse macrophages and human monocytes by recombinant mouse or human gamma interferon encapsulated in liposomes.
Fidler IJ
Ann Inst Pasteur Immunol (1985); 1986; 137C(2):212-5. PubMed ID: 3089125
[No Abstract] [Full Text] [Related]
40. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide.
Koff WC; Showalter SD; Hampar B; Fidler IJ
Science; 1985 Apr; 228(4698):495-7. PubMed ID: 2984772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
